Speaking from the American Society of Oncology (ASCO) 2018, held in Chicago, IL, Michael Mauro, MD, of Memorial Sloan Kettering Cancer Center, New York, NY, talks about the future uses of asciminib and other novel drugs currently being developed for chronic myeloid leukemia (CML), before mentioning his hopes for the future of this disease with regards to patient remission.
